Michael Zand – Page 799

Stem Cells Show Durable Benefit For Perianal Fistulas – Gastroenterology & Endoscopy News

2017-12-12 Michael Zand NEWS

Next Unicorn: Synthetic Biology Startup Ginkgo Bioworks? – Nanalyze

NanalyzeNext Unicorn: Synthetic Biology Startup Ginkgo Bioworks?NanalyzeThe unicorn has been a creature of legend and myth since at least the time of the ancient Greeks. You know the sort: a rare and magnificent beast, a gleaming, spiral horn protrudin… Continue reading

2017-12-12 Michael Zand NEWS

基因编辑2017年典型论文梳理 – 科学时报 (博客)

基因编辑2017年典型论文梳理科学时报 (博客)1月份，Cell发表张锋关于第二类CRISPR-Cas系统CRISPR/Cpf1的综述，介绍了新一代CRISPR基因组编辑系统，基于不同的效应蛋白家族，可以分为3种类型和9种亚型，其中譬如Cas9和Cas12a（Cpf1）。指出Cpf1系统更简单一些，它只 … Continue reading

2017-12-12 Michael Zand NEWS

Head to Head Comparison: Organovo (ONVO) versus Editas Medicine (EDIT) – TrueBlueTribune

Head to Head Comparison: Organovo (ONVO) versus Editas Medicine (EDIT)TrueBlueTribuneIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic a… Continue reading

2017-12-12 Michael Zand NEWS

Omalizumab improves efficacy of oral immunotherapy for multiple food allergies – EurekAlert (press release)

ScopeOmalizumab improves efficacy of oral immunotherapy for multiple food allergiesEurekAlert (press release)Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children… Continue reading

2017-12-12 Michael Zand NEWS

Drug increases speed, safety of treatment for multiple food allergies … – Stanford Medical Center Report

Stanford Medical Center ReportDrug increases speed, safety of treatment for multiple food allergies …Stanford Medical Center ReportCombining an antibody drug, omalizumab, with a procedure to desensitize children to multiple food allergies is safe and… Continue reading

2017-12-12 Michael Zand NEWS

ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM – MedPage Today

Stem Cells Show Durable Benefit For Perianal Fistulas
Gastroenterology & Endoscopy News
Orlando, Fla.—In a double-blind, phase 3 trial in patients with Crohn’s disease, stem cell treatment of perianal fistulas provided even better outcomes at 52 weeks than originally reported at 26 weeks. In Europe, where the trial was conducted …

2017-12-12 Michael Zand NEWS

ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM – MedPage Today

Medical Xpress

ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM
MedPage Today
ATLANTA – A single infusion of a gene therapy called bb2121 showed promise in heavily pre-treated multiple myeloma patients, offering a complete response that was sustained for beyond a year in some cases, researchers reported here. Of 18 patients …
‘Unheard of’ responses to bluebird CAR–T therapy seen in myeloma studyReuters
CAR T, immunotherapy bring new hope for multiple myeloma patientsMedical Xpress
#ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlightEndpoints News
OncLive –Business Wire (press release)
all 23 news articles »

2017-12-12 Michael Zand NEWS

1
…
797
798
799
800
801
…
3,823

Medical Xpress

Login

Cart

All posts by: Michael Zand

Stem Cells Show Durable Benefit For Perianal Fistulas – Gastroenterology & Endoscopy News

Next Unicorn: Synthetic Biology Startup Ginkgo Bioworks? – Nanalyze

基因编辑2017年典型论文梳理 – 科学时报 (博客)

Head to Head Comparison: Organovo (ONVO) versus Editas Medicine (EDIT) – TrueBlueTribune

Omalizumab improves efficacy of oral immunotherapy for multiple food allergies – EurekAlert (press release)

Drug increases speed, safety of treatment for multiple food allergies … – Stanford Medical Center Report

ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM – MedPage Today

ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM – MedPage Today